IMMUNOMEDICS REPORTS RESULTS OF NEW CANCER THERAPEUTIC
IMMUNOMEDICS REPORTS RESULTS OF NEW CANCER THERAPEUTIC WARREN, N.J., March 19 /PRNewswire/ -- Immunomedics, Inc.
(NASDAQ: IMMU), today reported, at the European Organization for Research and Treatment of Cancer meeting in Amsterdam, the results of a new cancer therapeutic involving loading large numbers of anticancer drugs to tumor-targeting antibodies used by Immunomedics. Immunomedics has licensed this new method of cancer treatment from the Center for Molecular Medicine and Immunology in Newark, N.J., where the preclinical testing of this therapeutic was conducted.
By the use of spacer molecules, 20-25 molecules of doxorubicin (cancer drug) have been successfully linked to the anticancer antibody that targets carcinoembryonic antigen (CEA), which is present in a wide variety of cancers, including colorectal, breast, lung, pancreatic, ovarian, and cervical. In a series of experiments involving human colorectal cancer growing in mice, it was found that a high retardation of growth of the human colorectal cancer could be achieved without adverse effects in the animals. "Doxorubicin is one of the most effective anticancer drugs currently in clinical use, and we hope to further increase its effectiveness by attaching the drug to cancer-targeting antibodies delivering the drug directly to the cancer site," stated Carl Pinsky, vice president, medical affairs. Immunomedics is planning to file an Investigational New Drug (IND) application with the FDA in order to commence Phase I human clinical trials using this new cancer therapeutic. Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections. -0- 3/19/92 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/ (IMMU) CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:
GK-OS -- NY023 -- 9553 03/19/92 09:45 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Mar 19, 1992|
|Previous Article:||LAURA ASHLEY AND FEDERAL EXPRESS BUSINESS LOGISTICS ANNOUNCE GLOBAL ALLIANCE|
|Next Article:||CENTRAL AND SOUTH WEST NAMES DIRECTOR OF MARKETING AND BUSINESS DEVELOPMENT|